Calon-Cardio's Fully Implantable ventricular assist device

Calon-Cardio 的完全植入式心室辅助装置

• 批准号: 10037229
• 金额: $ 62.55万
• 依托单位: CALON CARDIO-TECHNOLOGY LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10037229
• 关键词: Calon; Cardio; Fully; Implantable; ventricular

The majority of chronic heart disease patients ultimately suffer from heart failure. With the ageing of the population and advances in the treatment of cardiac disease, the number of patients with heart failure continues to increase. Although the majority of patients will remain stable for several years with standard medicines and surgery, a growing number will develop symptoms of advanced heart failure and may be referred for evaluation for heart transplantation. For selected patients who are too ill to wait for a heart donor or who are not eligible for a heart transplant because of age or other medical problems, ventricular assist devices (VADs) offer life-saving therapy and the only hope of returning to a good quality of life. Initially designed as temporary support to bridge patients to heart transplant, these devices are now being used as lifetime support or destination therapy. However, current technology is still imperfect with a recognised need to manage adverse events (AEs).This project will develop a Fully Implantable VAD to specifically address the main weaknesses of current VADs with a pump that offers improved haemodynamic performance, the elimination of driveline infection risk, lower manufacture and lifetime costs, and gives patients the freedom to perform everyday tasks unencumbered.The novel design of our new FIVAD will bring together expertise in mechanical engineering, electrical engineering, computational fluid dynamics, and biomedical engineering to deliver a novel pump and wireless energy technology.

大多数慢性心脏病患者最终会患上心力衰竭。随着人口老龄化和心脏病治疗的进步，心力衰竭患者的数量持续增加。虽然大多数患者在标准药物和手术治疗下将保持稳定数年，但越来越多的患者将出现晚期心力衰竭的症状，并可能被转诊进行心脏移植评估。对于那些因病情过重而无法等待心脏捐献者或因年龄或其他医疗问题而不符合心脏移植条件的选定患者，心室辅助装置（VAD）提供了挽救生命的治疗，也是恢复良好生活质量的唯一希望。这些设备最初被设计为临时支持，以连接患者到心脏移植，现在被用作终身支持或目的地治疗。然而，目前的技术仍然不完善，需要管理不良事件（AE）。本项目将开发一种完全植入式VAD，专门解决当前VAD的主要弱点，其泵可改善血液动力学性能，消除传动系感染风险，降低制造和寿命成本，我们新的FIVAD的新颖设计将汇集机械工程，电气工程，计算流体动力学，和生物医学工程，以提供一种新的泵和无线能源技术。